We bring
hope to life

People in dire medical need deserve
life-saving treatment.

Latest News

NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19...


Research Pipeline

Our product candidates include compounds in Phase 2, and Phase 3 trials for COVID-19-related Lung Injury and Acute Respiratory Failure (ARDS) in partnership with Relief Therape...

ZYESAMI™ (Aviptadil)


ZYESAMI™ (Aviptadil, previously RLF-100™), a synthetic form of human Vasoactive Intestinal Peptide (VIP) has been granted FDA Fast Track Designation for the investigational treatment of Cr...



NRx’s investigational drug regimen NRX-100/NRX-101, if approved by the FDA, would be the first sequential medicine regimen to include an oral therapeutic to treat Bipolar Depression in patients...

Bipolar Depression

Bipolar Depression in Patients with Acute Suicidal Ideation and Behavior (ASIB)

In the United States, More than 100 People End Their Lives Each Day

Nearly half of those who die of ...

Zyesami and NRX-100/NRX-101 are investigational therapies and have not been approved for human use by the Food and Drug Administration or European Medicines Agency.

Committed to
Life-Saving Treatments

NRx creates innovative, life-saving treatments to address unmet medical needs and bring hope to those with chronic conditions.

Meet Our Team